Looking into Fidelity National Finl’s Return on Capital Employed

Pulled from Benzinga Pro data Fidelity National Finl (NYSE:FNF) showed a loss in earnings since Q1, totaling $741.00 million. Sales, on the other hand, increased by 24.32% to $3.85 billion during Q2.

Pulled from Benzinga Pro data Fidelity National Finl (NYSE:FNF) showed a loss in earnings since Q1, totaling $741.00 million. Sales, on the other hand, increased by 24.32% to $3.85 billion during Q2. Fidelity National Finl reached earnings of $785.00 million and sales of $3.10 billion in Q1.

What Is ROCE?

Changes in earnings and sales indicate shifts in Fidelity National Finl’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Fidelity National Finl posted an ROCE of 0.08%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company’s recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Fidelity National Finl, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Analyst Predictions

Fidelity National Finl reported Q2 earnings per share at $2.06/share, which beat analyst predictions of $1.42/share.

Total
0
Shares
Related Posts
Read More

Evogene’s Earnings: A Preview

Evogene (NASDAQ:EVGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-26. Here's what investors need to know before the announcement. Analysts estimate that Evogene will report an earnings per share (EPS) of $-0.17.

EVGN